Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeneca B Regulatory News (SVCT)

Share Price Information for Seneca B (SVCT)

Share Price is delayed by 15 minutes
Get Live Data
44.00    0.00 (0.00%)
Bid:
43.00
Ask:
45.00
Spread: 2.00 (4.651%)
Market Cap: £14.56m
SVCT Live PriceLast checked at - London Stock Exchange

Intraday Seneca B Share Chart

NAV Update

1 Apr 2022 11:05

NAV Update

Net Asset Value(s)

Seneca Growth Capital VCT Plc (the "Company")

1 April 2022

Net asset value (“NAV”) update for the period ended 31 March 2022

The Directors and the Investment Manager of the Company, Seneca Partners Limited (“Seneca”), have reviewed the valuation of the Company’s Ordinary and B share investment portfolios as at 31 March 2022.

Ordinary Shares

As at 31 March 2022, the unaudited NAV of an Ordinary share was 29.0p per share.

This is a decrease of 0.2p from the previously published unaudited NAV as at 23 March 2022 of 29.2p and is principally due to a reduction in the value of the Ordinary share pool’s investment in AIM quoted Scancell Holdings Plc offset by an increase in the Ordinary share pool’s investment in AIM quoted Arecor Therapeutics Plc. As at 31 March 2022, shares in Scancell Holdings Plc were valued at 10.5p per share (23 March 2022: 11.5p) and shares in Arecor Therapeutics Plc were valued at 390p per share (23 March 2022: 350p). The Directors also reviewed the unquoted investments held in the Ordinary share portfolio and concluded that no changes were required to the carrying value of those investments.

No further investments or disposals have been made by the Ordinary share pool in the period since 24 March 2022 being the date up to which the post balance sheet events disclosure in the 31 December 2021 Annual Report related.

B Shares

As at 31 March 2022, the unaudited NAV of a B share was 96.7p per share.

This is a decrease of 3.4p from the previously published audited NAV as at 31 December 2021 of 100.1p and is due to changes in the value of the B share pool’s AIM quoted investments combined with the impact of running costs incurred in the period offset by profits realised from the sale of shares in some of the B share pool’s AIM quoted investments. The Directors also reviewed the unquoted investments held in the B share portfolio and concluded that no changes were required to the carrying value of those investments.

The B share pool made three additional investments in the quarter ending 31 March 2022:

£500k into the AIM IPO of Clean Power Hydrogen Plc, which has now been fully exited. £280k into AIM quoted Verici Dx Plc.£530k into AIM quoted Celadon Pharmaceuticals Plc.

For the purposes of calculating the unaudited net asset value per share for both share classes, quoted investments are carried at closing bid prices as at 31 March 2022 and unquoted investments are carried at fair value as at 31 March 2022.

The number of B shares in issue at 31 March 2022 was 14,588,659 and the number of Ordinary shares was 8,115,376. Therefore, the total number of voting rights in the Company is 22,704,035.

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

The Offer by the Company remains open for the 2021/22 tax year until midday on 4 April 2022.

For further information, please contact:

John Hustler, Seneca Growth Capital VCT Plc at john.hustler@btconnect.com

Richard Manley, Seneca Growth Capital VCT Plc at Richard.Manley@senecapartners.co.uk

Any enquiries regarding the offer for subscription of B shares should be directed to:

Matt Currie at Seneca Partners Limited on 01942 295 981 or at Matt.Currie@senecapartners.co.uk

Date   Source Headline
4th Jun 20261:34 pmRNSResults of Annual General Meeting voting
30th Apr 202612:12 pmRNSAnnual Report, Notice of AGM and new NAVs
20th Mar 20264:36 pmRNSUnaudited Net asset value (“NAV”) Update
28th Nov 202512:06 pmRNSShare Buy-back and Total Voting Rights
11th Nov 202512:11 pmRNSSecond Interim Dividend on B Shares
21st Oct 20252:40 pmRNSPDMR Shareholding
15th Oct 20254:26 pmRNSUpdated NAV & Ordinary Share Class Dividend
26th Sep 20251:50 pmRNSUnaudited Half-year Report for 6m to 30 June 2025
8th Aug 20254:05 pmRNSIssue of Equity and Total Voting Rights
2nd Jun 20253:15 pmRNSShare Buy-back and Total Voting Rights
22nd May 20251:20 pmRNSResult of AGM
12th May 20254:02 pmRNSInterim Capital Dividend on Ordinary Shares
7th May 20253:04 pmRNSIssue of Equity and Total Voting Rights
29th Apr 20253:58 pmRNSIssue of Supplementary Prospectus
23rd Apr 20254:15 pmRNSFinal results and Notice of AGM
4th Apr 20253:37 pmRNSIssue of Equity and Total Voting Rights
3rd Apr 20257:00 amRNSNet Asset Value(s)
19th Mar 20257:00 amRNSInterim Dividend on B Shares
11th Dec 20242:44 pmRNSDirector/PDMR Dealing
11th Dec 20242:39 pmRNSIssue of Equity and Total Voting Rights
15th Nov 20243:15 pmRNSShare Buy-back and Total Voting Rights
14th Nov 20243:32 pmRNSSecond Interim Dividend on B Shares
16th Oct 20247:00 amRNSNet Asset Value(s)
12th Sep 20242:11 pmRNSOffer for Subscription and Prospectus Publication
9th Aug 20243:20 pmGNWIssue of Equity and Total Voting Rights
6th Aug 202410:10 amGNWClosure of Offer for Subscription
25th Jul 20247:00 amGNWHalf-year Report
15th May 202412:16 pmGNWResult of AGM
1st May 20243:34 pmGNWIssue of Equity and Total Voting Rights
1st May 20247:00 amGNWB Share Net Asset Value
22nd Apr 202410:46 amGNWShare Buy-back and Total Voting Rights
5th Apr 202412:44 pmGNWIssue of Equity and Total Voting Rights
4th Apr 20247:00 amGNWNet Asset Value(s)
28th Mar 202412:11 pmGNWIssue of Supplementary Prospectus
22nd Mar 20247:00 amGNWFinal Results, Notice of AGM, Updated NAV
7th Mar 20247:00 amGNWInterim Dividend on B Shares
19th Feb 20244:36 pmGNWDirector Declaration
21st Dec 202312:03 pmGNWIssue of Equity and Total Voting Rights
6th Dec 20233:24 pmGNWDirector/PDMR Dealing
6th Dec 20233:14 pmGNWIssue of Equity and Total Voting Rights
29th Nov 202312:36 pmGNWChange of the Company’s Auditor
20th Nov 20233:20 pmGNWB Share Buy-back and Total Voting Rights
3rd Nov 20237:00 amGNWDividend Declaration
12th Oct 20237:00 amGNWNet Asset Value(s)
11th Oct 20233:39 pmGNWDirectorate Change
24th Aug 20234:18 pmGNWOffer for Subscription and Publication of Prospectus
18th Aug 20235:08 pmGNWIssue of Equity and Total Voting Rights and Capital Reorganisation
2nd Aug 202311:40 amGNWHalf-year Report
30th Jun 20231:58 pmGNWIssue of Equity and Total Voting Rights
20th Jun 20238:50 amGNWShare Buy-back and Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.